Northwestern University Feinberg School of Medicine

The Ken & Ruth Davee Department of Neurology

Clinical Trials

Our current active protocols are listed below. If you have any questions about the particular study protocol, please contact the study coordinator.  For more information about the research or participation in general, please call our office at 312-695-8643.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

Trials
National Parkinson Foundation Patient Registry
The purpose of this study is to collect registry data to examine the relationship between clinical symptoms and treatment in PD patients. Data collected will be used to describe differences in current treatment practices across many sites to evaluate tre…
The purpose of this study is to collect registry data to examine the relationship between clinical symptoms and treatment in PD patients. Data collected will be used to describe differences in current treatment practices across many sites to evaluate treatment and ultimately improve patient care.
• Patients diagnosed with idiopathic Parkinson’s Disease
• Must have established care with a movement disorder specialist at Northwestern
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00014255
More Info

For more information on this study please contact us:

Friedeck, Heidi 312 503 1522
Platelet-Orientated Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, h…
The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke.
Bernstein, Richard ABernstein, Richard A
STU00023167
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression
This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls…
This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
Genetic Cohort-PD Subjects
• Have at least two of the following: resting tremor, slowness of movement, muscle rigidity
• Parkinson disease diagnosis for 7 years or less
• Male or female 18 years or older
• Confirmation of LRRK2, GBA, or SNCA genetic mutation
• Willing to undergo genetic testing

Genetic Cohort-Unaffected Subjects
• 50 years or older with LRRK2/GBA mutation or first degree relative with LRRK2/GBA mutation
• Willing to undergo genetic testing
OR
• 30 years or older with SNCA mutation or first degree relative with SNCA mutation
• Willing to undergo genetic testing
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT01141023 STU00031752
More Info

For more information on this study please contact us:

Friedeck, Heidi 312 503 1519
Peripheral Neuropathy Research Registry (PNRR)
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in t…
National Peripheral Neuropathy Research Registry, a collection of different types of information, such as patient medical, family, and social histories and blood samples. The information is carefully maintained so that it can be studied repeatedly in the future. The registry aims to help researchers’ access large amounts of information about people with PN. By using this registry, researchers will facilitate both basic and clinical research studies that will bring improved understandings of the etiology (origination) and pathogenesis (development) of PN. They will specifically ask why some patients with peripheral neuropathy develop neuropathic pain and others do not, and what the characteristics of patients with painful peripheral neuropathy are in terms of their symptoms, examination findings, and blood tests. Ultimately this research may result in improved diagnosis, more effective treatments, and possibly prevention.
Inclusion criteria: 1. Diabetic Peripheral Neuropathy 2. Chemo-therapy Induced Peripheral Neuropathy 3. HIV-induced Peripheral Neuropathy 4. Idiopathic Peripheral Neuropathy; Exclusion criteria: Any other type of Peripheral Neuropathy
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00048864
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. …
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Bernstein, Richard ABernstein, Richard A
NCT01468701 STU00062959
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure
The purpose of this study is to observe mothers with and without epilepsy, along with their children, from pregnancy until age 6 and assess the developmental and neurocognitive influence of anti-epileptic medicatio…
The purpose of this study is to observe mothers with and without epilepsy, along with their children, from pregnancy until age 6 and assess the developmental and neurocognitive influence of anti-epileptic medications.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
NCT01730170 STU00070411
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
Non-Invasive Marker of Ovarian Reserve in Women with Epilepsy
The purpose of this study is to assess and compare AMH hormone levels in women with epilepsy vs. healthy controls, utilizing medical history questionnaires and a finger stick.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
STU00077630
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
Parkinson’s Disease and Movement Disorders Center Biorepository
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the regi…
This is a registry aimed to collect biologic and clinical information, such as blood and tissue samples, and family and medical histories from patients diagnosed with a movement disorder. The purpose of studying materials from the registry is to identify factors that either cause these neurologic conditions or increase one’s risk for developing them. Samples collected for this biorepository include a blood sample (or a saliva sample) and a skin biopsy. Participants may choose to donate one or both samples.
• Diagnosis of a movement disorder
• Male or female 5 years of age or older when diagnosed
• Genetic mutation related to a movement disorder
• Family members of patients with movement disorders
Simuni, TatyanaSimuni, Tatyana
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00091585
More Info

For more information on this study please contact us:

Hernandez, Alejandro +1 312 503 2778
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
Carotid revascularization for primary prevention of stroke (CREST-2) is a multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in…
Carotid revascularization for primary prevention of stroke (CREST-2) is a multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asymptomatic high-grade carotid stenosis. One trial will randomize patients in a 1:1 ratio to endarterectomy versus no endarterectomy and another will randomize patients in a 1:1 ratio to carotid stenting with embolic protection versus no stenting. Medical management will be uniform for all randomized treatment groups and will be centrally directed.
Eskandari, MarkEskandari, Mark
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02089217 STU00200290
More Info

For more information on this study please contact us:

Toaspern, Lillian 312 695 3410
Circadian rhythms and epilepsy: a prospective study
This study is to further understand the link between epilepsy, sleep and circadian rhythms. We propose to characterize sleep-wake and circadian rhythm patterns in patients with epilepsy (PWE). To assess the interactions between circadian function an…
This study is to further understand the link between epilepsy, sleep and circadian rhythms. We propose to characterize sleep-wake and circadian rhythm patterns in patients with epilepsy (PWE). To assess the interactions between circadian function and sleep quality with seizure frequency and timing by data from self- reported sleep and circadian chronotype questionnaires, sleep diaries, seizure type and frequency as reported by the subjects’ primary physician, and objective sleep (actigraphy) and circadian rhythm measures.
Adults (18 years of age and older) with generalized seizures and focal seizures.
Patients are allowed to remain on their usual regimen of antiepileptic medications.

Zee, Phyllis CZee, Phyllis C
STU00201284
More Info

For more information on this study please contact us:

Erlikh, Natanie 1-888-NU-STUDY
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
This study is looking at generalize tonic-clonic (GTC) seizure control for generalized epilepsie…
This study is looking at generalize tonic-clonic (GTC) seizure control for generalized epilepsies using Lacosamide. We are recruiting participants with generalized epilepsies over the age of 18, who are experiencing at least 2 GTCs per month.
Macken, Micheal PMacken, Micheal P
NCT02408523 STU00201161
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
Attention Bias: Testing a Potential Marker for the Diagnosis of Atypical Movement Disorders
The purpose of this study is to determine whether problems with attention lead to abnormal movements. The study involves a few thinking tests to determine if certain patterns of thinking or focusing can be ass…
The purpose of this study is to determine whether problems with attention lead to abnormal movements. The study involves a few thinking tests to determine if certain patterns of thinking or focusing can be associated with abnormal movements.
• Adult patients with a clinically established or documented psychogenic movement disorder
• Adult patients with a diagnosis of benign familial/ essential tremor as made by a movement disorder specialist
• Healthy adults who do not have any suspected or known neurologic movement disorders

Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00202673
More Info

For more information on this study please contact us:

Hernandez, Alejandro +1 312 503 2778
Phase 3 Gene Therapy for Painful Diabetic Neuropathy
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic neuropathy. A total of 477 subjects will be randomized in a 2:1 ratio to o…
The purpose of this study is to determine the safety and efficacy of bilateral intramuscular injections of VM202 versus placebo in the treatment of painful diabetic neuropathy. A total of 477 subjects will be randomized in a 2:1 ratio to one of two treatment groups: Treatment - VM202 - 318 subjects Control - Placebo (VM202 vehicle) - 159 subjects Randomization will be stratified by current use of gabapentin and/or pregabalin.
1. 18-75 years, 2. Type 1 or 2 diabetes, 3. no significant changes to diabetes medication in last 3 months, 4. No new symptoms associated with diabetes for last 3 months, 5. Diagnosis of diabetic peripheral neuropathy in both lower limbs, 6, lower limb pain for at least 6 months, 7. No history of cancer. 8. No active infection or immuno-supression. 9. No amputations due to diabetes. 10. No proliferative diabetic retinopathy.
Ajroud-Driss, SendaAjroud-Driss, Senda
NCT02427464 STU00202112
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease
The objective of this study is to determine the mechanisms of stroke in patients with Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of antegrade flow through the sten…
The objective of this study is to determine the mechanisms of stroke in patients with Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of antegrade flow through the stenotic artery, distal tissue perfusion to the affected territory, and artery-to-artery embolism. The hypothesis is that non-invasive imaging biomarkers that stratify stroke risk and distinguish mechanisms of IAD. This prospective multicenter study will enroll 175 patients with recently symptomatic high-grade IAD. Patients will be studied within 21 days of the index event (allowing appropriate time to arrange for diverse imaging modalities), with the following advanced neuroimaging techniques to elucidate mechanisms of recurrent ischemia: - Quantitative magnetic resonance imaging (QMRA) to assess volumetric flow rate through the stenotic artery. - Magnetic resonance perfusion weighted imaging (PWI-MRI) to determine distal tissue perfusion. - Vasomotor reactivity by Transcranial Doppler using the breath-holding technique (BHI-TCD) to assess compensatory flow characteristics to the territory distal to the affected artery; - Transcranial Doppler with embolic signal monitoring to evaluate artery-to-artery embolism that reflects plaque instability. Patients will receive standardized medical management and its effectiveness on blood pressure, lipid, and glycemic control will be monitored. The primary outcome is recurrent stroke in the territory of the stenotic artery during a 1-year follow-up period; secondary outcomes are: a) new asymptomatic ischemic lesions on MRI in the distribution of the stenotic artery at 6-8 weeks, and b) transient ischemic attack (TIA) in the distribution of the stenotic artery during a 1-year follow-up period. Patients will be recruited at various sites that will be trained and certified on the imaging techniques employed. Raw imaging data will be interpreted centrally.
Inclusion
1- Symptomatic stroke/TIA due to IAD

2- Stenosis 70-99% measured on CTA/DSA/MRA as SOC (WASID criteria) and MRA flow gap (send to bay state)


3-Stroke/TIA diagnosed on CT or MRI

3- TIA with DWI abnormalities or ≥2 stereotyped events (weakness, aphasia)

5- IAD-Intracranial Carotid
MCA, Intracranial Vertebral,
Basilar

6- Age >30;
7- 30-49 also IAD in another vascular bed (coronary, extracranial carotid, peripheral) or the presence of 2 or more risk factors (hypertension, diabetes mellitus, hyperlipidemia, tobacco abuse within the last 2 years).

8- Enrollment within 21 days of index event

.
Exclusion
1- No ACA No PCA
2- Other cause of stroke/TIA besides ICAD
3- Angioplasty/stenting performed or planned on target vessel or on a vessel proximal to it.
4- Contraindications to MRI,
5- Pregnancy, lactation, morbid obesity, and severe claustrophobia.
6- Cr >1.5 mg/dL or GFR <30 ml/min/1.73 m2;
7- Known allergy to gadolinium.

Ansari, Sameer AhmadAnsari, Sameer Ahmad
NCT02121028 STU00202274
More Info

For more information on this study please contact us:

Muzaffar, Ayesha 312 926 4251
Multidisciplinary Treatment for Obstructive Sleep Apnea and Insomnia
The MATRICS Study - This study aims to investigate the effectiveness of different combinations and sequences of evidence-based treatment strategies for people with both Obstructive Sleep Apnea and Insomnia. Participants will be rand…
The MATRICS Study - This study aims to investigate the effectiveness of different combinations and sequences of evidence-based treatment strategies for people with both Obstructive Sleep Apnea and Insomnia. Participants will be randomly assigned to one of three treatment conditions using a medical device known as CPAP, or using this device in combination with a behavioral treatment to improve sleep.
Inclusion Criteria:
Males and Females age 18 and older;
Meets criteria for Obstructive Sleep Apnea;
Meets criteria for an Insomnia Disorder; Able to make around 15 in-person visits over 7-9 months.
Exclusion Criteria:
Comorbid medical condition that requires immediate treatment of OSA;
Severe cases of OSA that require immediate treatment;
Psychiatric conditions that may interfere with study protocol or uncontrolled psychiatric conditions that require immediate treatment;
Comorbid sleep disorders that require treatment outside of the study protocol;
Other sleep-related breathing disorder besides OSA;
Excessive daytime sleepiness that requires immediate treatment or presents significant risk;
CPAP use or formal CBT for insomnia within the past 6 months.
Ong, Jason COng, Jason C
NCT01785303 STU00203478
More Info

For more information on this study please contact us:

Yap, Bonnie 312 503 6627
Enroll-HD: A Prospective Registry Study in a Global Huntington’s Disease Cohort
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers wil…
The purpose of this research study is to collect clinical information about patients and their health. We will also collect biological samples, such as blood and DNA (the genetic material in your blood). Researchers will use this information and samples to learn more about HD and to try to find new treatments for the disease. People from many countries contribute to Enroll-HD.
Individuals 18 yrs or older affected by Huntington's Disease (HD) or from a HD family or are a "community control" (a person who does not carry the HD genetic mutation that causes Huntington's disease and is not part of an HD family, but would like to participate in the study). Research visits are conducted yearly and will consists of a collection of medical and family history and biological samples.
Bega, DannyBega, Danny
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
STU00203021
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121
The Role of Circadian Dysfunction in Hepatic Encephalopathy in Patients with Cirrhosis
Individuals with advanced liver disease (cirrhosis) often report new or worsening sleep problems. Additionally, cirrhosis increases
1) Diagnosis of end-stage liver disease or cirrhosis; 2) being evaluated for liver transplant; 3) Age >=18yo; 4) fluent in English; 5) no severe kidney disease (for example, patients currently on dialysis are not eligible)
Kim, MinjeeKim, Minjee
  • Map it 201 E. Huron St.
    Chicago, IL
STU00204423
More Info

For more information on this study please contact us:

Kim, Minjee 312 695 7976
Clinical Research Consortium for the Study of Cerebellar Ataxia (CRC-SCA) to Study Natural History and Genetic Modifiers in Spinocerebellar Ataxia (SCA)
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurolo…
The purpose of this study is to collect natural history data among ataxia patients in a cohort of SCA 1, 2, 3, 6 patients using clinic-based neurological rating scales and performance measures. Another study goal is to identify new measures of ataxia, cognition, and neurobehavior in comparison to traditional clinician rating methods. The gene analysis is expected to establish a relationship, if any, between age at onset of disease and disease progression rates.
• Age 18 and older
• Presence of symptoms and signs of ataxia
• Molecular diagnosis of SCA 1, 2, 3, 6 either in the participant or an affected family member
• Willingness to participate in the study and ability to give informed consent.
Opal, PuneetOpal, Puneet
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT01060371 STU00204294
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121
Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of GZ/SAR402671 in patients with early-stage Parkinson’s disease carrying a GBA mutation or other pre-specified variant.
A study to assess an experimental oral d…
A study to assess an experimental oral drug (GZ/SAR402671) in patients with early-stage Parkinson’s disease carrying a GBA mutation or other pre-specified variant. There are 2 parts to this trial. Part 1 will be conducted to decide what will be the best dose of the study drug to use in Part 2 of this trial. The total expected duration of this study will be approximately 11 months for Part 1 and 12 months for Part 2.
Male or female subjects with a diagnosis of PD and who are heterozygous carriers of a GBA mutation.
Simuni, TatyanaSimuni, Tatyana
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT02906020 STU00204431
More Info

For more information on this study please contact us:

Poon, Cynthia 312 503 8216
Expanded Access Protocol of Patisiran for Patients with Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
This Expanded Access Program (EAP) is intended to provide greater access to patisiran (a drug currently being investigated by the FDA) for patients with sympto…
This Expanded Access Program (EAP) is intended to provide greater access to patisiran (a drug currently being investigated by the FDA) for patients with symptomatic hATTR amyloidosis with polyneuropathy. It is not a clinical trial. Interested patients will be consented, screened, and their redacted information will be reviewed by an independent adjudication committee to determine study eligibility. If found to be eligible, patients will enroll in the EAP for as long as the drug is being investigated by the FDA. Research patients will receive patisiran infusions every 3 weeks. Before the infusion, research patients will receive pre-medications to prevent a reaction to the study drug. Patisiran is administered as an IV infusion over 70-minutes. Research patients will be asked to remain at the study site for 1-hour after the infusion for monitoring. Research patients will not be compensated for their participation but receive patisiran free of charge for the duration of the study. During the EAP, research patients will also be asked to provide blood and urine samples and answer questionnaires.
Eligible patients include patients who are 18 years of age or older, with a documented TTR mutation and a confirmed diagnosis of symptomatic hATTR amyloidosis with polyneuropathy established through neurologic consultation, Karnofsky Performance Status ≥50%, and a PND score I to III.
Ajroud-Driss, SendaAjroud-Driss, Senda
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT02939820 STU00204718
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 7504
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
SPI2 is a Phase III clinical trial investigating the safety and efficacy of MD1003 (high dose biotin) in patients with primary or secondary progressive MS. Research patients will be randomly placed …
SPI2 is a Phase III clinical trial investigating the safety and efficacy of MD1003 (high dose biotin) in patients with primary or secondary progressive MS. Research patients will be randomly placed into one of two groups; a study drug and placebo (a sugar pill that is not the study drug). The first part of the study will last for at least 15 months, followed by an extension period of up to 12 months where both groups will get the study drug. Throughout the study, both groups of research patients will be asked to provide blood and urine samples, complete MRIs, and answer questionnaires.
(1) Signed and dated written informed consent, (2) Patient aged 18-65 years old, (3) Diagnosis of primary or secondary progressive MS, (4) Documented evidence of clinical disability progression within the 2 years prior to inclusion, (5) EDSS at inclusion from 3.5 to 6.5, (6) TW25 < 40 seconds, (7) Kurtzke pyramidal functional subscore ≥2 defined as “minimal disability
Cohen, Bruce ArnoldCohen, Bruce Arnold
  • Map it 675 N. St. Clair St. Suite 20-100
    Chicago, IL
NCT02936037 STU00204784
More Info

For more information on this study please contact us:

Joslin, Benjamin 312 503 5183
Genetic causes and pathogenic mechanisms of adult epilepsies
The purpose of this study is to look at genetic markers of epilepsy in patients and their families using blood, saliva, skin, and brain tissue analysis.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
STU00205877
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
cIRB: Topiramate as a disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)
This is a 96-week placebo-controlled trial of topiramate at a target dose of 100 mg daily (50 mg twice daily) as a potentially disease altering therapy for Cryptogenic Sensory Peripheral Neuropathy
INCLUSION: 1. Age 18-75; 2. Diagnosis of confirmed cryptogenic symptomatic distal symmetric peripheral polyneuropathy; 3. Prediabetes based on American Diabetes Association; 4. No history of prior therapy with topiramate; 5. Waist circumference >102 cm for men, >88 cm for women
Menichella, DanielaMenichella, Daniela
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT02878798 STU00206049
More Info

For more information on this study please contact us:

Ward, Tina 312 503 2128
Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects with Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial (Protocol SEP093-701)
The purpose of this open-label, non-…
The purpose of this open-label, non-randomized study is to assess the efficacy of Eslicarbazepine as first add-on medication for patients already on Levetiracetam of Lamotrigine, or as later add-on therapy for patients with focal epilepsy.
Gerard, Elizabeth ErwayGerard, Elizabeth Erway
NCT03116828 STU00205762
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy
The purpose of this study is for patients with first-time implants of a Vagus Nerve Stimulator (VNS) to have the new Microburst stimulation settings optimized using fMRI scans.
Macken, Micheal PMacken, Micheal P
NCT01281293 STU00206259
More Info

For more information on this study please contact us:

Bellinski, Irena Iva 312 926 1672
Clinical Trial Readiness for SCA1 and SCA3
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain…
Subjects must be 18-65 years of age with symptoms of ataxia or a diagnosis of SCA1 or SCA3 or have an affected family member. Subjects with a previous diagnosis of early stage SCA1 or SCA 3 may also be eligible. Subject must be able to undergo a MRI (brain scan) and not weigh over 300 lbs.
Subjects aged 18 to 65 with presence of symptomatic ataxic disease or asymptomatic mutation carrier or subjects with definite molecular diagnosis of SCA1 or SCA3 or another affected family member or Subjects of age >18 with previous diagnosis of early stage SCA1 and SCA3. Subjects must not make changes in physical/occupational therapy status within two months prior to enrollment. Subjects must not weigh over 300 lbs.
5) 6) No changes in sical/occupational therapy status within two months prior to enrolment
Opal, PuneetOpal, Puneet
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00206988
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121
A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Months.
The primary objective of this study is to evaluate the effi…
The primary objective of this study is to evaluate the efficacy of the drug WTX101 administered for 48 weeks, compared to standard of care (SoC), on copper (Cu) control in subjects with Wilson's disease aged 18 and older.
Diagnosis of Wilson's Disease, Treatment for >28 days with chelation therapy, Zn therapy or a combination of chelator and Zn; willing to avoid the use of vitamins and/or minerals containing CU, Zn or Mo throughout the study, willing to undergo > 48-hour washout from current WD treatment
Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
NCT03403205 STU00206921
More Info

For more information on this study please contact us:

Brown, ZsaZsa 312 503 4121
A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients with Parkinson’s Disease.
The purpose of this study is to learn more about the effects of treatment with IPT803 on PD symptoms and how it impacts your daily life. The study will also look at whether or not yo…
The purpose of this study is to learn more about the effects of treatment with IPT803 on PD symptoms and how it impacts your daily life. The study will also look at whether or not your personal characteristics, like age, gender or personality traits, affect how well IPT803 works. A number of research studies have been published showing that treatments similar to IPT803 have an effect on the outcome of PD studies • There is very low risk of side effects or allergies associated with IPT803, and it is generally well tolerated • IPT803 will not interact with your usual PD treatment or diet • You will be informed of the nature of IPT803 treatment received during the last study visit
-Are at least 35 years of age
-Have been diagnosed with idiopathic Parkinson’s Disease (PD) (H&Y < 3 and MMSE ≥ 26)
-Have been stabilized with PD medication(s) for at least 4 weeks prior to the first study or have never received PD medication(s)
Bega, DannyBega, Danny
  • Map it Lavin Pavillion 259 E. Erie St., Suite 19-100
    Chicago, IL
STU00207166
More Info

For more information on this study please contact us:

Coffey, Taylor 1 312 503 1819